ラサギリン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ラサギリン" in Japanese language version.

refsWebsite

Global rank Japanese rank

17nih.gov

4^th place

24^th place

13doi.org

2^nd place

6^th place

2pmda.go.jp

6,690^th place

394^th place

2fda.gov

447^th place

1,043^rd place

1molecularneurodegeneration.com

low place

1takeda.com

low place

1wiley.com

222^nd place

498^th place

1docs.google.com

1,047^th place

3,204^th place

1pharmamedtechbi.com

low place

1jpost.com

544^th place

2,030^th place

1haaretz.com

497^th place

2,728^th place

docs.google.com

US 3,513,244. See US patent 5453446, lines 50-60. US Patent 5453446 was the patent at issue in Teva v Watson, see page 2

doi.org

“An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells”. Neuroscience Letters 326 (2): 105–8. (June 2002). doi:10.1016/s0304-3940(02)00332-4. PMID 12057839.
“Rasagiline: a review of its use in the management of Parkinson's disease”. Drugs 67 (12): 1725–47. (2007). doi:10.2165/00003495-200767120-00006. PMID 17683172.
“Pharmacology and neuroprotective properties of rasagiline”. Journal of Neural Transmission. Supplementum 48: 95–101. (1996). doi:10.1007/978-3-7091-7494-4_9. PMID 8988465.
“Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease”. CNS Drugs 22 (7): 563–86. (2008). doi:10.2165/00023210-200822070-00003. PMID 18547126.
“Rasagiline for the treatment of Parkinson's disease: an update”. Expert Opinion on Pharmacotherapy 16 (14): 2231–41. (2015). doi:10.1517/14656566.2015.1086748. PMID 26364897.
“Therapeutic advances in multiple system atrophy and progressive supranuclear palsy”. Movement Disorders 30 (11): 1528–38. (September 2015). doi:10.1002/mds.26334. PMID 26227071.
“From a Parkinson's disease expert: Rasagiline and the future of therapy”. Molecular Neurodegeneration 2 (1): 13. (July 2007). doi:10.1186/1750-1326-2-13. PMC 1929084. PMID 17617893.
“Rasagiline”. Nature Reviews. Drug Discovery 4 (8): 625–6. (August 2005). doi:10.1038/nrd1803. PMID 16106586.
“Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline”. Neuroscience Letters 355 (3): 169–72. (January 2004). doi:10.1016/j.neulet.2003.10.067. PMID 14732458.
“Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research”. Journal of Neural Transmission. Supplementum 48: 61–73. (1996-01-01). doi:10.1007/978-3-7091-7494-4_6. ISBN 978-3-211-82891-5. PMID 8988462.
Chen, Jack J.; Swope, David M. (2005-08-XX). “Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease” (英語). The Journal of Clinical Pharmacology 45 (8): 878–894. doi:10.1177/0091270005277935.
“Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis”. Journal of Medicinal Chemistry 48 (26): 8148–54. (December 2005). doi:10.1021/jm0506266. PMC 2519603. PMID 16366596.
“Therapeutic advances in multiple system atrophy and progressive supranuclear palsy”. Movement Disorders 30 (11): 1528–38. (September 2015). doi:10.1002/mds.26334. PMID 26227071.

fda.gov

accessdata.fda.gov

Azilect Prescribing Information Label last revised May, 2014

fda.gov

“Peripheral and Central Nervous System Advisory Committee Background Package on Azilect”. FDA. 2011年12月7日閲覧。

haaretz.com

“FDA Advisers Refuse Teva Plea to Expand Azilect Label”. Reuters and Haaretz (2011年10月19日). 2021年4月29日閲覧。

jpost.com

“Making armor for the brain”. The Jerusalem Post (2010年11月13日). 2021年4月29日閲覧。

molecularneurodegeneration.com

“From a Parkinson's disease expert: Rasagiline and the future of therapy”. Molecular Neurodegeneration 2 (1): 13. (July 2007). doi:10.1186/1750-1326-2-13. PMC 1929084. PMID 17617893.

nih.gov

pubmed.ncbi.nlm.nih.gov

“An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells”. Neuroscience Letters 326 (2): 105–8. (June 2002). doi:10.1016/s0304-3940(02)00332-4. PMID 12057839.
“Rasagiline: a review of its use in the management of Parkinson's disease”. Drugs 67 (12): 1725–47. (2007). doi:10.2165/00003495-200767120-00006. PMID 17683172.
“Pharmacology and neuroprotective properties of rasagiline”. Journal of Neural Transmission. Supplementum 48: 95–101. (1996). doi:10.1007/978-3-7091-7494-4_9. PMID 8988465.
“Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease”. CNS Drugs 22 (7): 563–86. (2008). doi:10.2165/00023210-200822070-00003. PMID 18547126.
“Rasagiline for the treatment of Parkinson's disease: an update”. Expert Opinion on Pharmacotherapy 16 (14): 2231–41. (2015). doi:10.1517/14656566.2015.1086748. PMID 26364897.
“Therapeutic advances in multiple system atrophy and progressive supranuclear palsy”. Movement Disorders 30 (11): 1528–38. (September 2015). doi:10.1002/mds.26334. PMID 26227071.
“From a Parkinson's disease expert: Rasagiline and the future of therapy”. Molecular Neurodegeneration 2 (1): 13. (July 2007). doi:10.1186/1750-1326-2-13. PMC 1929084. PMID 17617893.
“Rasagiline”. Nature Reviews. Drug Discovery 4 (8): 625–6. (August 2005). doi:10.1038/nrd1803. PMID 16106586.
“Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons”. The Journal of Pharmacology and Experimental Therapeutics 259 (2): 841–7. (November 1991). PMID 1658311.
“Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline”. Neuroscience Letters 355 (3): 169–72. (January 2004). doi:10.1016/j.neulet.2003.10.067. PMID 14732458.
“Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research”. Journal of Neural Transmission. Supplementum 48: 61–73. (1996-01-01). doi:10.1007/978-3-7091-7494-4_6. ISBN 978-3-211-82891-5. PMID 8988462.
“Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis”. Journal of Medicinal Chemistry 48 (26): 8148–54. (December 2005). doi:10.1021/jm0506266. PMC 2519603. PMID 16366596.
“Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy”. Therapeutics and Clinical Risk Management 3 (3): 467–74. (June 2007). PMC 2386362. PMID 18488080.
“Therapeutic advances in multiple system atrophy and progressive supranuclear palsy”. Movement Disorders 30 (11): 1528–38. (September 2015). doi:10.1002/mds.26334. PMID 26227071.

ncbi.nlm.nih.gov

pharmamedtechbi.com

US 3,513,244. See US patent 5453446, lines 50-60. US Patent 5453446 was the patent at issue in Teva v Watson, see page 2

pmda.go.jp

info.pmda.go.jp

“アジレクト錠1mg／アジレクト錠0.5mg 添付文書”. www.info.pmda.go.jp. PMDA. 2021年4月28日閲覧。
“アジレクト錠1mg／アジレクト錠0.5mg インタビューフォーム”. PMDA. 2021年4月28日閲覧。

takeda.com

“パーキンソン病治療剤「アジレクト錠」の日本における製造販売承認取得について”. www.takeda.com. 2021年4月28日閲覧。

wiley.com

doi.wiley.com

Chen, Jack J.; Swope, David M. (2005-08-XX). “Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease” (英語). The Journal of Clinical Pharmacology 45 (8): 878–894. doi:10.1177/0091270005277935.